🔍
Therapeutic Treating or Preventing Enthesopathy
Case ID:
C14476
Report of Invention:
11/9/2016
Web Published:
1/5/2018
Unmet Need
Over half of sports injuries involve tendons and entheses (the sites of attachment between ligament and bone). Enthesopathy, a disorder involving the attachment of tendon or ligament, represents one-fourth of tendon diseases and is a difficult disorder to treat. Tendon disorders, which include enthesopathy, represent a considerable socioeconomic burden, with an estimated annual cost in healthcare and indirect loss of wages of $850 billion. Despite its high prevalence, the cell signaling mechanisms that contribute to its pathogenesis remains unknown. Consequently, there are no disease-modifying therapies at present for enthesopathy and orthopedic surgery is the only treatment option.
Technology Overview
Johns Hopkins researchers have generated two independent mouse models of enthesopathy pathogenesis: a semi-Achilles tendon transection model (SMTS) and a dorsiflexion immobilization model (DI). The role of TGF-β in musculoskelatal disease has drawn increasing attention in recent years, where activated TGF-β has been shown to recruit mesenchymal stromal/stem cells (MSCs) to maintain tissue homeostasis. The researchers have shown that TGF-ß was activated in tendon-bone insertions in both the SMTS and DI models. Their work suggests that inhibition of elevated levels of active TGF-ß could serve as potential therapy.
Stage of Development
The inventors have generated two mouse models that reproduce enthesopathy pathogenesis. The researchers have shown that high concentrations of active TGF-ß in these models led to excessive vessel formation, bone deterioration and fibrocartilage calcification, thereby contributing to enthesopathy. Conversely, treatment of the SMTS mice with a neutralizing monoclonal antibody against TGF-β (1D11) attenuated the enthesopathy pathology compared to mice injected with a vehicle antibody. These models may provide valuable tools for screening potential therapeutics targeting the TGF-ß pathway involved in enthesopathy.
Publications
J Clin Invest.
2018;128(2):846–860
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
METHODS FOR THE PREVENTION AND TREATMENT OF ENTHESOPATHY AND RELATED DISORDERS
PCT: Patent Cooperation Treaty
United States
16/763,597
11,680,094
5/13/2020
6/20/2023
5/9/2039
Granted
Direct Link:
https://jhu.technologypublisher.com/technology/26830
Inventors:
Category(s):
Clinical and Disease Specializations, Clinical and Disease Specializations > Musculoskeletal, Clinical and Disease Specializations > Rheumatology, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Targets,
Get custom alerts for techs in these categories/from these inventors:
Subscribe for JHTV Updates
For Information, Contact:
Sahil Aggarwal
sahil.aggarwal@jhu.edu
410-614-0300
Save This Technology:
Bookmark this page
Download as PDF
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum